Lemonaid Health (part of 23andMe)

23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was named as one of the San Francisco Chronicle's Top Workplaces and one of Comparably's Best Places to Work in 2022. CEO, Anne Wojcicki was also named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in 2021 and 2022. More information is available at www.23andMe.com.

Doctor On Demand

GlaxoSmithKline

Casdin Capital

Fidelity

Fidelity Management and Research Company

Foresite Capital

Altimeter Capital

Anne Wojcicki

Richard Branson

Sean Tiner

Future Planet Capital

Raj Luhar

SharesPost Investment Management

NewView Capital

Pegasus Tech Ventures

Sequoia Capital

ACE & Company

Rancilio Cube

23andMe

This #BlackHistoryMonth, we’re sharing quotes from Black leaders in STEM who continue to inspire us every day. Mae Jemison became the first African-American woman to travel into space when she served as a mission specialist aboard the Space Shuttle Endeavour in 1992.

We’re looking for a Sr. Scientist II to join our Research Team! In this role, you will have the opportunity to provide scientific input and strategic direction for research initiatives involving the lung cancer cohort. https://lnkd.in/guC-u3bT

Earlier this year, researchers with the National Institutes of Health, in collaboration with 23andMe and about a dozen other groups, published the largest to-date genetic study of Parkinson’s disease. This is the first large-scale genetics study of Parkinson’s disease to include data from individuals from multiple ancestral populations. 

https://23and.me/3SmIqHS

We are excited to announce the U.S. FDA has cleared the investigational new drug application for 23ME-01473 (‘1473), a natural killer (NK) cell activator intended to treat cancer.

“This program further validates the 23andMe database as a proven resource for identifying novel therapeutic targets,” said Jennifer Low, Head of Therapeutics Development, 23andMe. “The team is excited to initiate our next immuno-oncology program, ‘1473, which is particularly interesting given its two mechanisms of action, which may synergise to enhance NK and T cell immunity against certain tumors.” 

Read more here: https://lnkd.in/gKQMP6Ka

Has there ever been a time – maybe during a stressful moment, or even just out of the blue – when you started to feel dizzy, like your vision was narrowing, and like you were disconnected from your body? 

About 1 in 3 people will experience a panic attack in their lifetime. Panic attacks happen when fear and anxiety overwhelm a person and lead to physical symptoms such as a racing heart, stomach aches, or shortness of breath. 

Our 23andMe+ Premium Panic Attacks report (Powered by 23andMe Research) helps individuals better understand their genetic likelihood of developing panic attacks throughout their lifetime. https://23and.me/426saOl

We're excited to share that the FDA  included our BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report clearance and PCCP in their 2023 Annual Report for device innovation. 

Check out the report here: https://lnkd.in/evgJZnXh

January is Thyroid Awareness Month. In 2022, we released a 23andMe+ Premium report on Hashimoto’s disease, powered by 23andMe research. 

Hashimoto’s disease is an autoimmune condition in which the immune system causes the thyroid gland to become inflamed and damaged, and over time produce less thyroid hormone. This condition can cause many different symptoms like fatigue or depression, and if left untreated, can be associated with other health conditions like heart problems. 

Members can learn about their genetic likelihood of developing it and actions they can take to promote thyroid and immune health. https://23and.me/3u87E3n

Our very own Dr. Noura Abul-Husn is speaking at the Precision Medicine World Conference this week in Silicon Valley on January 25th! If you’re planning to attend make sure you stop by for her showcase.

At 23andMe, we believe the ability to identify, recruit, and characterize research participants based on genetics unknown to them is a critical capability for our therapeutics and research teams to inform drug development and genetics research.

https://23and.me/48zaTQv

When Emily decided to do a 23andMe, she expected to learn more about her health, genealogy, and all of the “fun stuff DNA can tell you,” but her results led to something unexpected, and expanded what she understood about herself and her family. 

https://23and.me/3HnVW7O

23andMe - DNA Testing

23andMe Mobile

Domain Not Resolving

DNSSEC

Google Maps

WordPress

Amazon

Font Awesome

Mobile Non Scaleable Content

Organization Schema

reCAPTCHA

Person Schema

Associate General Counsel

Andrea Henry

Co-Founder and CEO

Chief Product Officer

Daniel Chu

VP of Engineering and Chief Security Officer

David Baker

General Counsel & Privacy Officer

Jacquie Cooke Haggarty

Chief Scientific Officer

Joe Arron

Chief Marketing Officer

Jon Ward

Chief Administrative Officer

Kathy Hibbs

Vice President & Chief Architect

Mike Polcari

Team Operations and Logistics, Office of the CEO

Stephanie Chan

George Church

Esther Dyson

Roelof Botha

Neal Mohan

Patrick Chung

Richard Scheller

Chief Science Officer and Head of Therapeutics

Chief Legal and Regulatory Officer

Chief Security Officer

Kenneth Hillan

Head of Therapeutics

David Weisburd

Investor

Joyce fung

Vice President, Research

Steve Lemon

VP, Product & Engineering

Doctor On Demand is a mobile app that provides on-demand and scheduled visits with U.S.-licensed health care providers.

San Francisco Bay Area Companies With More Than 500 Employees

Silicon Valley Public Companies

Western US Companies With More Than $1M in Revenue (Top 10K)

Female Founded Investors active in San Francisco Bay Area

23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits.

A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007.

The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings.

23andMe allows its clients/users to study their ancestry, genealogy and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data.

One reason the Google investment in 23andMe made sense was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.

Post-IPO Equity - 23andMe

Series F - 23andMe

Secondary Market - 23andMe

National Institutes of Health

Grant - 23andMe

Series E - 23andMe

Series D - 23andMe

Series C - 23andMe

Computer and Software Services and Scientific Services

Sunnyvale

California

United States

North America

23andMe, tech companies disclose hundreds of Bay Area job cuts

Relative Risk: Home DNA tests could pose privacy risk

23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation

Genetic Testing Delivers Startup Hits And Misses

Tech Layoffs: US Companies That Cut Jobs In 2022, 2023 And 2024

23andMe customer? Here's what to know about the privacy of your genetic data.

23andMe lays off 40% of its workforce, ends therapeutics division

23andMe cuts workforce by 40%

23andMe cuts 40% of its workforce and discontinues therapeutics division

An advanced health membership offering clinical-grade exome sequencing, biannual blood tests, and personalized recommendations with access to genetics-informed clinicians.

An annual membership providing ongoing personalized health reports, including pharmacogenetics and cancer risk insights, with new features added regularly.

A service combining ancestry insights with health predisposition, wellness, and carrier status reports to understand genetic health risks.

A comprehensive ancestry analysis covering over 3,000 geographic regions, with features like DNA Relative Finder and automatic family tree building.

Canada

United Kingdom

Europe

The Netherlands

Australia

Oceania

HTML5

Google Fonts

Vimeo

Wordpress

Bootstrap

Facebook Comments

HubSpot Forms

Thawte SSL

Google Doubleclick

Google Tag Manager

LivingDNA offers a health kit that is around $50 cheaper than 23andMe's, providing information about disease predisposition, nutrition, and exercise insights.

LivingDNA

Orig3n provides a holistic view of individuals through DNA tests covering health, wellness, genetics, and behavioral analysis, offering affordable tests.

Orig3n

Ancestry is a popular competitor to 23andMe, offering DNA testing services and global ancestry composition breakdown.

Ancestry

23andMe Holding Co. is a publicly trading personal genomics and biotechnology company based in South San Francisco, California. It provides a direct-to-consumer genetic testing service, offering reports on ancestry and genetic predispositions to health-related topics.

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

news impact assignment basic	general	Feb 16, 2024 12:41 AM	19f748e8
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:09 AM	657b953f
crunchbase profile	general	Nov 25, 2024 11:35 AM	c3f4b8e4
li profile	general	Feb 16, 2024 12:41 AM	c65eefdb
translate crunchbase fundingrounds	general	Nov 25, 2024 2:14 PM	cc1120a1
peers	general	Feb 16, 2024 12:41 AM	5a9869ce
news basic	general	Feb 16, 2024 12:41 AM	fae7e280
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:23ANDME

23andMe Holding Co.

Last Close

3.23

22/11 21:00

Market Cap

225.52M

Beta: -

Volume Today

514.98K

Avg: -